ICCC NASDAQ
ImmuCell Corporation
1W: -1.8%
1M: -2.5%
3M: -3.1%
YTD: +64.7%
1Y: +47.7%
3Y: +80.6%
5Y: -0.1%
$9.75
+0.15 (+1.56%)
Weekly Expected Move ±3.1%
$9
$9
$10
$10
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
2 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (40)
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
Top Research Reports for Alphabet, Mastercard & AbbVie
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next?
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
ImmuCell (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) doubles profit on higher First Defense sales - Stock Titan
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
Top Stock Reports for JPMorgan, Novartis & Qualcomm
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ImmuCell (ICCC) Q1 2026 Earnings Transcript
Here’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
Top Stock Reports for Goldman Sachs, NextEra Energy & Shopify
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
ImmuCell sees preliminary Q1 revenue of $10.4M
Stocks to watch after market on Wednesday: ICCC, COST, STZ
ImmuCell Q1 sales jump 28.4% to $10.4M, led by Tri-Shield demand
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
Maine governor backs millionaire tax as Senate primary tightens
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Here’s Why
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
ImmuCell (NASDAQ:ICCC) Shares Cross Above Two Hundred Day Moving Average – Here’s Why
ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve
ImmuCell outlines plan to boost First Defense capacity to 5–6M units while strengthening U.S. market share
ImmuCell GAAP EPS of -$0.31, revenue of $7.62M
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
Earnings Scheduled For March 4, 2026
ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?
Niche Focus & Regulation Shape the Future of Healthcare Firms
ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
ImmuCell (NASDAQ:ICCC) Stock Passes Below 200-Day Moving Average – What’s Next?
ImmuCell's Two-Product Edge in Cattle Health Fuels Growth
ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength